2011 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) | Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG ; Mok T.S.K. | Journal of Clinical Oncology | 1256 | 1128 | |